After its share price was "halved" shortly after listing, Hanx Biopharmaceuticals (03378.HK) saw a strong recovery in the first quarter of 2026. As of March 26, it closed at HK$27.64, with a cumulative 2026 gain of 72.97%. The rebound is primarily driven by the approval of HX111—a global First-in-Class OX40-targeted ADC—to enter clinical trials. While the R&D pipeline holds 10 candidate drugs and the core product HX009 (PD-1/SIRPαbispecific) has completed Phase I trials in multiple regions, Phase III studies have yet to begin, indicating a significant cycle remains before commercialization.
On March 26, Easy Click Worldwide Network Technology Co., Ltd. submitted a listing application to the Hong Kong Stock Exchange, with CITIC Securities serving as the sole sponsor. As a digital marketing service provider dedicated to empowering Chinese enterprises' global expansion, Easy Click offers end-to-end marketing solutions through its proprietary systems (Cyberklick, Yeahmobi and zMaticoo). According to China Insights Consultancy, based on total transaction value in 2024, the company ranked fourth among Chinese digital marketing service providers for enterprises' global expansion, and third among global independent third-party mobile advertising platforms targeting the Chinese market.
PATEO CONNECT (02289.HK), hailed as the "first stock of intelligent cockpit," has recently undergone a deep price correction. As of March 25, 2026, it closed at HK$107.30, down over 60% from its February high and nearing its HK$102.23 offer price. Despite revenue doubling to RMB 2.557 billion (2022-2024), the company has seen cumulative net losses of RMB 1.497 billion. With a loss of RMB 220 million in the first five months of 2025, the profit turning point has yet to be reached. While domestic penetration hit 75.9% in 2025, margin recovery remains challenged by the ongoing price wars among downstream automakers.
GEO enters its operational deployment phase in 2026, as financial institutions pivot their evaluation criteria from binary presence ("have or have not") to scientific efficacy and measurable impact. Youliancloud proposes four golden standards: systematic monitoring, citation-rate penetration through traffic flows, faithful restoration of official investment research logic, and constructing multi-dimensional closed-loop systems for sustainable long-term positioning.
On March 23, Huaqin Technology Co., Ltd. submitted a listing application to the Hong Kong Stock Exchange (HKEX), with CICC and BofA Securities acting as joint sponsors. As a platform-based enterprise with over 20 years of deep engagement in the intelligent product sector, Huaqin Technology provides global technology companies with intelligent products covering mobile terminals, computing and data centers, AIoT and innovative businesses.
As the "first stock of automotive reusable packaging," ALSCO Pooling (02649.HK) listed in early March 2026. By March 24, it closed at HK$4.08, a cumulative drop of 62.91% from its HK$11 IPO price. The company is China’s second-largest reusable packaging service provider, with its core "shared operations" business accounting for 75.5% of revenue. Despite being in the "green economy" tailwind, the industry is highly fragmented, with the top five players holding only a 4.7% market share. Profitability fluctuates significantly, and accounts receivable account for over 60% of revenue, with turnover days consistently exceeding 160 days.
Shanghai FourSemi Semiconductor Co., Ltd. (03625.HK) officially launched its H-share IPO on March 23, 2026, with an offer price range of HK$40 to HK$50 per share, 100 shares per lot and an admission fee of approximately HK$5,050.43. The Company is expected to list on the Main Board of the Hong Kong Stock Exchange on April 2, 2026.As a leading enterprise in China's power amplifier audio chip sector, FourSemi focuses on the design and R&D of low-power audio chips, medium-to-high power audio chips and haptic feedback chips, holding an important position in the trend of domestic substitution.
As the first domestic energy drink giant to achieve an "A+H" listing, Eastroc Beverage (09980.HK) debuted on the Hong Kong Stock Exchange in February 2026. Despite stellar performance in 2025—with revenue expected to surpass RMB 20 billion (a year-on-year increase of approx. 31%-33%) and net profit growth exceeding 30%—its performance in the secondary market remains weak. As of March 23, the H-shares closed at HK$208.40, down nearly 16% from the IPO price of HK$248. The core product, "Eastroc Super Drink," contributes over 74% of revenue. While the "1+6" strategy is progressing, diversification faces intense competition from powerful rivals like Nongfu Spring and Genki Forest.
Benefiting from the trends of Embodied Intelligence and AI Agents, the Hong Kong-listed Chapter 18C specialist technology stock Yunji (02670.HK) has shown strong recent performance. As of March 20, 2026, it closed at HK$198.50, with a year-to-date increase of 82.11%. The company is currently upgrading from a single hardware manufacturer to a full-scenario intelligent service ecosystem provider, collaborating with SF Cityrush to roll out the "robot + rider" relay mode to 15,000 hotels nationwide. While 2025 revenue reached RMB 300 million (+23.1% YoY), the annual loss widened to RMB 295 million, and the adjusted net loss surged by 310.5% YoY, exhibiting the typical "high investment for growth" characteristic.
HANGZHOU TONGSHIFU CULTURAL AND CREATIVE (GROUP) CO., LTD. (00664.HK) officially launched its H-share IPO on March 23, 2026, with an offer price range of HK$60 to HK$68 per share, 100 shares per lot and an entry fee of HK$6,868.57. The company is expected to list on the Main Board of the Hong Kong Stock Exchange on March 31, 2026.As the absolute leader in China's copper cultural and creative craft products market, the company has built a strong brand barrier in the cultural and creative sector with its unique positioning of "traditional craftsmanship + modern design".
Since its H-share debut in January 2026, domestic memory chip leader GigaDevice (03986.HK) has been a capital market favorite. As of March 19, its shares closed at HK$433.80, up 167.78% from the offer price. Expected 2025 revenue is approximately RMB 9.203 billion (+25%), with net profit reaching RMB 1.61 billion (+46%). This growth is primarily driven by the "AI Memory Chip Cycle," which optimized supply-demand structures. Driven by a surge in demand for AI servers and data centers, global memory chip prices have spiked, with some products rising over 130% month-on-month; a tight supply-demand balance is expected to persist until 2027.
Following a massive surge of nearly 12 times in the previous period, 160 Health (02656.HK) suffered a heavy blow on March 18, 2026, closing at HK$103.40 with a single-day drop of 31.52%, wiping out over HK$16 billion in market value. The day before the crash, the company issued a positive profit alert for 2025, expecting an adjusted net profit of RMB 3 million to 5 million, its first annual profit since listing, mainly due to significantly reduced operating expenses through AI empowerment. While benefiting from the Stock Connect and AI agent concepts, the key to its valuation stability remains whether it can convert "registration platform" traffic into a solid AI competitive moat in a fragmented market surrounded by giants like JD Health and AliHealth.
HQVT's second HKEX filing highlights its status as a market leader in China's multispectral AI and large model services. While 2025 revenue reached RMB 669 million with improved gross margins, the company faces a 27% dip in net profit and a significant operating cash outflow of RMB 130 million. As the perception intelligence market is projected to reach RMB 412.4 billion by 2029, HQVT's ability to balance aggressive growth with financial risk control will be its defining challenge post-listing.
Since being included in the Stock Connect in March 2026, Qingsong Health (02661.HK) has seen strong share price gains. As of March 17, it closed at HK$126.6, up 458.20% from its IPO price, with a market cap of HK$26.13 billion. The company has successfully pivoted from insurance services to digital integrated health services, with the latter accounting for 76.7% of revenue in H1 2025. However, this transition has triggered a surge in costs, causing gross margin to plunge from 82.6% to 32.5%. Additionally, active users have dropped sharply from 71 million to 23 million, posing serious challenges to user retention and acquisition momentum.
Following a roughly 40% decline in early March, CF PharmTech (02652.HK) closed up 21.39% at HK$27.92 on March 16, 2026, spurred by positive catalysts. On March 13, the IND application for its inhalation dry powder ICF001 (for PAH and PH-ILD) was accepted by the NMPA, potentially filling a domestic void in PH-ILD treatment. While the company has 6 marketed products, its core product CF017 (Budesonide Inhalation) accounts for over 90% of revenue, leaving its risk-resistance structure fragile. The current TTM P/E of 384.57x reflects high market expectations for the innovation pipeline but also carries the risk of a valuation pullback.
This guide advocates for a paradigm shift in financial digital asset evaluation via YouLianCloud GEOPlus. It introduces a three-tier framework: the Information Layer focuses on official recall rates for semantic accuracy; the Data Layer emphasizes structural compliance to boost source authority; and the Communication Layer targets multi-source citation frequency to build algorithmic consensus. This L3 standard ensures financial brands achieve high-weight, high-trust visibility in the generative AI search era.
